ReAlta is a clinical-stage biotech company that develops a new class of drugs to address life-threatening diseases.
ReAlta Life Sciences has raised $40.0M in total funding. The most recent round was Undisclosed. The last funding was announced in April 2026.
ReAlta Life Sciences's investors include National Institute of Allergy and Infectious Diseases, Virginia Catalyst, Marathon Pharmaceuticals, Children’s Research Holdings.
ReAlta Life Sciences is headquartered in Norfolk, United States.
ReAlta is a clinical-stage biotech company that develops a new class of drugs to address life-threatening diseases.
ReAlta Life Sciences is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ReAlta Life Sciences — Funding & Investors." VCBacked, April 8, 2026, https://www.vcbacked.co/company/realta-life-sciences. Accessed July 22, 2026.
VCBacked. (2026). ReAlta Life Sciences — Funding & Investors. Retrieved July 22, 2026, from https://www.vcbacked.co/company/realta-life-sciences
{{cite web |title=ReAlta Life Sciences — Funding & Investors |url=https://www.vcbacked.co/company/realta-life-sciences |website=VCBacked |access-date=July 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated